newsfilter
← Latest News
PR Newswire·

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

IDYA
  • 130 progression-free survival (PFS) events for the Phase 2/3 OptimUM-02 trial of darovasertib & crizotinib in first-line HLA*A2-negative metastatic uveal melanoma were confirmed by BICR, with topline results expected by the last week of March 2026.
  • Darovasertib is anticipated to be in three Phase 3 registrational trials across metastatic, neoadjuvant, & adjuvant uveal melanoma settings by the first half of 2026.
  • IDEAYA targets initiation of a registrational study for IDE849 (DLL3 TOP1 ADC) monotherapy in the second-line/refractory setting for small cell lung cancer &/or neuroendocrine carcinomas by the end of 2026.
  • Preliminary clinical data from the global Phase 1 trial of IDE849 is expected by the end of 2026.
  • IDEAYA held approximately $1.05 billion in cash, cash equivalents, & marketable securities as of December 31, 2025, sufficient to fund operations into 2030.
  • Collaboration revenue totaled $10.9 million for the three months ended December 31, 2025, compared to $7.0 million in the prior year period.
  • Research & development expenses were $86.6 million for the three months ended December 31, 2025, down from $140.2 million in the same period of 2024.
  • General & administrative expenses were $18.8 million for the three months ended December 31, 2025, up from $11.0 million in the prior year period.
  • The net loss was $83.3 million for the three months ended December 31, 2025, compared to $130.3 million in the same period of 2024.
  • The net loss was $113.7 million for the full year ended December 31, 2025, compared to $274.5 million for the full year 2024.
  • GSK notified IDEAYA of its intention to terminate the 2020 collaboration agreement, with GSK transferring the IDE275 & IDE705 clinical programs to IDEAYA.
  • IND clearance was received for IDE034 (B7H3/PTK7 bispecific TOP1 ADC) in Q4 2025, with first-patient-in expected in Q1 2026.
  • IDE574 (KAT6/7 dual inhibitor) received IND clearance in January 2026, with Phase 1 initiation targeted for Q1 2026.
  • Enrollment of 437 patients in the OptimUM-02 trial is complete, with overall survival data expected to support a full approval filing for first-line HLA*A2-negative metastatic uveal melanoma.